Fulcrum Therapeutics, Inc. has announced its financial results for the fourth quarter and full year of 2024, reporting a cash position of $241 million, providing a runway into at least 2027. The ...
Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Free Report) – Research analysts at HC Wainwright lowered their Q1 2025 earnings estimates for shares of Fulcrum Therapeutics in a report released on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback